PBLite is the ECHOLASER Thermal Ablation treatment for malignant abdominal tumours, in particular primary and secondary liver cancers.

PBLite is indicated in the treatment of primitive and secondary liver cancer in the form of focal lesions. PBLite is also a safe and effective treatment for those who, due to critical medical conditions, are unable to undergo surgery.

PBlite circle

What is it?

With just one PBLite session it is possible to treat liver lesions with a very wide size range and diameters of up to 5 cm thanks to the versatility provided by the multi-fibre approach. The localized thermal effect of PBLite makes it the gold standard for liver lesions close to structures at risk.

PBLite consists of the percutaneous insertion of optical fibres (from 1 to 4 depending on the size of the tumour), and the delivery of laser energy for several minutes, which heats the tissues until they are completely destroyed with a sufficient safety margin. The positioning of the applicators, monitoring of the treatment and verification of the effective coagulation area are all carried out under ultrasound guidance. In order to facilitate the insertion manoeuvre, the system has dedicated multi-applicator Guiding Systems for ultrasound probes designed for the anatomical area of the liver with relative Biopsy Software that displays the guidelines on the screen. As these are malignant tumours, the objective of the treatment is a complete ablation of the lesion and subsequent absence of local post-treatment relapses and a net increase in the long-term survival probability (5 years).



  • complete ablation with a sufficient safety margin
  • “in situ” thermal destruction
  • preservation of the healthy tissue and the organ function
  • highly predictable and repeatable coagulation volume as required for the safety margin
  • localized thermal effect in the target volume only, which makes the treatment possible close to sites at risk
  • use of fine, non-traumatic needles for liver organ
  • possibility of treating patients with pace-makers (excellent electromagnetic compatibility)
  • no general anesthesia
  • short duration of the treatment (few minutes)
  • rapid recovery
  • no or insignificant post-treatment pain
  • brief hospitalization
  • bridging therapy for organ transplants

For more information including clinical cases, publications, and clinical trials visit: www.elesta-echolaser.com